Journal article
Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies
WP Sheridan, CG Begley, LB To, A Grigg, J Szer, D Maher, MD Green, PA Rowlings, KM McGrath, J Cebon, P Dyson, D Watson, J Bayly, E De Luca, D Tomita, E Hoffman, G Morstyn, CA Juttner, RM Fox
Bone Marrow Transplantation | STOCKTON PRESS | Published : 1994
Abstract
The hemopoietic growth factor filgrastim (r-metHu G-CSF) stimulates granulopoiesis after autologous BMT and can also be used as a peripheral blood progenitor cell (PBPC)-mobilizing agent. Rapid platelet recovery follows the addition of filgrastim-mobilized PBPC to autologous BMT. We have now studied 29 adults with malignant lymphoma, Hodgkin's disease or ALL to assess the ability of filgrastim-mobilized PBPC to rapidly and durably restore hemopoiesis without bone marrow (BM) infusion. Patients with a high yield of PBPC from three leukaphereses, defined as > 30 x 104/kg GM-CFC, were eligible for PBPC transplant without BM. Patients with a low yield of GM-CFC received both PBPC and BM infusion..
View full abstract